Tranylcypromine: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
No edit summary
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
No edit summary
Line 3: Line 3:
|genericName=Tranylcypromine
|genericName=Tranylcypromine
|aOrAn=a
|aOrAn=a
|drugClass=MAO
|drugClass=MAOIs
|indication=major depressive disorder
|indication=major depressive disorder
|hasBlackBoxWarning=Yes
|hasBlackBoxWarning=Yes
Line 78: Line 78:
|fileName=Parnate
|fileName=Parnate
|drugName=Tranylcypromine
|drugName=Tranylcypromine
|NDC=24987-447-10  
|NDC=24987-447-10
|drugAuthor=Covis Pharmaceuticals Inc
|drugAuthor=Covis Pharmaceuticals Inc
|ingredients=cellulose, microcrystalline, anhydrous citric acid, croscarmellose sodium, d&c red no. 7, fd&c blue no. 2, fd&c red no. 40, fd&c yellow no. 6, gelatin, lactose, magnesium stearate, talc, titanium dioxide
|ingredients=cellulose, microcrystalline, anhydrous citric acid, croscarmellose sodium, d&c red no. 7, fd&c blue no. 2, fd&c red no. 40, fd&c yellow no. 6, gelatin, lactose, magnesium stearate, talc, titanium dioxide

Revision as of 09:17, 6 June 2014

Tranylcypromine
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

TITLE
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Tranylcypromine is a MAOIs that is FDA approved for the {{{indicationType}}} of major depressive disorder. There is a Black Box Warning for this drug as shown here. Common adverse reactions include edema, weight gain, constipation, loss of appetite, nausea, xerostomia, asthenia, dizziness, headache, insomnia, somnolence, agitation, worsening, anxiety, impotence.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Major depressive disorder
  • 30 mg/day PO, after 2 weeks, may increase by 10 mg/day every 1-3 weeks to a :*Maximum dose of 60 mg/day

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Tranylcypromine in adult patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Tranylcypromine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Safety and effectiveness in children have not been established

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Tranylcypromine in pediatric patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Tranylcypromine in pediatric patients.

Contraindications

There is limited information regarding Tranylcypromine Contraindications in the drug label.

Warnings

TITLE
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

There is limited information regarding Tranylcypromine Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Tranylcypromine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Tranylcypromine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Tranylcypromine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Tranylcypromine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tranylcypromine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Tranylcypromine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Tranylcypromine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Tranylcypromine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Tranylcypromine in geriatric settings.

Gender

There is no FDA guidance on the use of Tranylcypromine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Tranylcypromine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Tranylcypromine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Tranylcypromine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Tranylcypromine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Tranylcypromine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Tranylcypromine Administration in the drug label.

Monitoring

There is limited information regarding Tranylcypromine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Tranylcypromine and IV administrations.

Overdosage

There is limited information regarding Tranylcypromine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Px
Tranylcypromine
Systematic (IUPAC) name
(±)-trans-2-phenylcyclopropan-1-amine
or
(1R*,2S*)-2-phenylcyclopropan-1-amine
Identifiers
CAS number 155-09-9
ATC code N06AF04
PubChem 19493
DrugBank DB00752
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 133.19 g/mol
SMILES eMolecules & PubChem
Synonyms Transamine
Pharmacokinetic data
Bioavailability 50%[1]
Metabolism Liver (by enzymes CYP2A6, CYP2C19, CYP2D6, MAOA, and MAOB)
Half life 2.5 hours[1]
Excretion Urine, Feces[1]
Therapeutic considerations
Pregnancy cat.

C(AU) ?(US)

Legal status

Prescription Only (S4)(AU) ?(CA) POM(UK) [[Prescription drug|Template:Unicode-only]](US) Template:Unicode Prescription only

Routes Oral

Mechanism of Action

There is limited information regarding Tranylcypromine Mechanism of Action in the drug label.

Structure

There is limited information regarding Tranylcypromine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Tranylcypromine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Tranylcypromine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Tranylcypromine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Tranylcypromine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Tranylcypromine How Supplied in the drug label.

Storage

There is limited information regarding Tranylcypromine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Tranylcypromine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Tranylcypromine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Tranylcypromine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Tranylcypromine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Tranylcypromine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Tranylcypromine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ 1.0 1.1 1.2 Williams, David A. (2007). = R0W1ErpsQpkC&pg = PA590 "Antidepressants" Check |chapterurl= value (help). In Foye, William O.; Lemke, Thomas L.; Williams, David A. Foye's Principles of Medicinal Chemistry. Hagerstwon, MD: Lippincott Williams & Wilkins. pp. 590–1. ISBN 0-7817-6879-9.

{{#subobject: 

 |Page Name=Tranylcypromine
 |Pill Name=Parnate
 |Drug Name=Tranylcypromine
 |Pill Ingred=cellulose, microcrystalline, anhydrous citric acid, croscarmellose sodium, d&c red no. 7, fd&c blue no. 2, fd&c red no. 40, fd&c yellow no. 6, gelatin, lactose, magnesium stearate, talc, titanium dioxide|+sep=;
 |Pill Imprint=PARNATE;SB
 |Pill Dosage=10.00 mg
 |Pill Color=Red|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=4.00
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Covis Pharmaceuticals Inc
 |NDC=24987-447-10

}}

{{#subobject: 

 |Label Page=Tranylcypromine
 |Label Name=Tranyl1.PNG

}}

{{#subobject: 

 |Label Page=Tranylcypromine
 |Label Name=Tranyl2.PNG

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Tranylcypromine&oldid=976141"